IRIS
FAVOINO, ELVIRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.814
AS - Asia 1.520
EU - Europa 1.131
SA - Sud America 406
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 6.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.770
SG - Singapore 628
CN - Cina 384
BR - Brasile 353
IT - Italia 313
HK - Hong Kong 240
SE - Svezia 218
RU - Federazione Russa 168
VN - Vietnam 108
DE - Germania 101
UA - Ucraina 76
GB - Regno Unito 75
FI - Finlandia 63
FR - Francia 42
IN - India 37
ID - Indonesia 29
AR - Argentina 28
BD - Bangladesh 21
CA - Canada 18
CI - Costa d'Avorio 17
PL - Polonia 16
MX - Messico 15
TR - Turchia 14
AT - Austria 13
BE - Belgio 12
JP - Giappone 12
IQ - Iraq 8
NL - Olanda 8
UZ - Uzbekistan 8
ZA - Sudafrica 8
ES - Italia 7
MY - Malesia 6
PK - Pakistan 6
CO - Colombia 5
DZ - Algeria 5
IE - Irlanda 5
PY - Paraguay 5
CL - Cile 4
EG - Egitto 4
PE - Perù 4
AZ - Azerbaigian 3
CR - Costa Rica 3
EC - Ecuador 3
HR - Croazia 3
KE - Kenya 3
MA - Marocco 3
TH - Thailandia 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BW - Botswana 2
DO - Repubblica Dominicana 2
EE - Estonia 2
JO - Giordania 2
LT - Lituania 2
SA - Arabia Saudita 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AO - Angola 1
AU - Australia 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
EU - Europa 1
GA - Gabon 1
GR - Grecia 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
PH - Filippine 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
ZM - Zambia 1
Totale 6.925
Salva come PNG Salva come JPEG
Città #
Fairfield 421
Ashburn 382
Chandler 311
Singapore 286
Woodbridge 263
Houston 251
Hong Kong 240
Bari 210
Jacksonville 206
Ann Arbor 189
Nyköping 186
Cambridge 184
Seattle 180
Wilmington 167
Beijing 127
Nanjing 72
Roxbury 63
Lawrence 60
New York 53
Boardman 49
Dallas 43
Los Angeles 43
Des Moines 41
Princeton 36
Ho Chi Minh City 34
Inglewood 34
Moscow 27
Dearborn 22
Hanoi 21
São Paulo 21
Pune 20
Jakarta 19
London 19
Santa Clara 19
Shenyang 19
Brooklyn 18
Buffalo 18
Abidjan 17
Munich 16
San Diego 16
Warsaw 16
Dong Ket 14
Paris 14
Belo Horizonte 13
Chicago 13
Noicattaro 13
Brussels 12
Tokyo 12
Guangzhou 11
Nanchang 11
Rio de Janeiro 11
Orem 10
Tianjin 10
Boston 9
Hebei 9
Rome 9
San Francisco 9
Atlanta 8
Chennai 8
Council Bluffs 8
Tashkent 8
Changsha 7
Denver 7
Falkenstein 7
Frankfurt am Main 7
Montreal 7
Nuremberg 7
Poplar 7
Stockholm 7
Vienna 7
Ankara 6
Haiphong 6
Helsinki 6
Indiana 6
Jiaxing 6
Mexico City 6
The Dalles 6
Amsterdam 5
Auburn Hills 5
Columbus 5
Curitiba 5
Dublin 5
Fortaleza 5
Johannesburg 5
Kunming 5
São José dos Campos 5
Toronto 5
Turin 5
Washington 5
Wuhan 5
Buenos Aires 4
Campinas 4
Falls Church 4
Hải Dương 4
Kilburn 4
Kuala Lumpur 4
Lima 4
Marseille 4
Porto Alegre 4
Salvador 4
Totale 4.841
Salva come PNG Salva come JPEG
Nome #
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 182
ANTIBODIES TO ENDOPLASMIN AND THEIR USE 170
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 169
Methods for treating a tumor using an antibody that specifically binds HMW-MAA 166
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 160
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 158
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 158
Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis 157
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 146
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 142
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 138
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 134
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 131
CD20 mimicry by a mAb rituximab-specific linear peptide: A potential tool for active immunotherapy of autoimmune diseases 130
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 124
Abstract 4390: Heat shock protein (HSP) Grp94-targeted combinatorial immunotherapy for pancreatic cancer 120
CD20 mimicry by mAb Rituximab-specific linear peptide. A potential tool for active immunotherapy of autoimmune diseases 117
Rheumatic disorders as paraneoplastic syndromes 113
Effects of Adjuvants for Human Use in Systemic Lupus Erythematosus (Sle)-Prone (Nzb/Nzw) F1 Mice 113
CD20: A target antigen for immunotherapy of autoimmune diseases 112
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor 110
The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells 110
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 106
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 104
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides 103
Novel combinatorial therapy for pancreatic adenocarcinoma 100
CSPG4 in cancer: Multiple roles 99
Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report 98
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes 96
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors 95
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence 94
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 93
Response to "Is active acid sphingomyelinase required for the antiproliferative response to rituximab?" [e-letter]. http://bloodjournal.hematologylibrary.org/content/117/13/3695.citation/reply#bloodjournal_el_2268 91
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 91
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 91
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 89
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 88
Targeting cancer initiating cells in pancreatic adenocarcinoma 86
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: Implication for peptide-based active immunotherapy 85
Harnessing host innate immunity may combat acquired resistance to BRAFi 83
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 82
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4 82
Characterization of the specificity of the Human scFv W9 82
Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis. 81
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 78
null 77
Circulating Inhibitory Factor 1 levels in adult patients with Prader-Willi syndrome 76
HLA allele prevalence in disease-modifying antirheumatic drugs-responsive enthesitis and/or arthritis not fulfilling ASAS criteria: Comparison with psoriatic and undifferentiated spondyloarthritis 74
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope 74
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS 72
Insight into the specificità of the anti-CD20 monclonal antibody Rituximab. 71
Raynaud’s phenomenon: from molecular pathogenesis to therapy 71
AUTO-ANTIBODIES TO THE AMINO TERMINAL SEGMENT (AMINOACID 1-17) OF CENP-A DISPLAY A UNIQUE SPECIFICITY IN SYSTEMIC SCLEROSIS AND ARE INDEPENDENTLY EXPRESSED FROM THOSE AGAINST CENP-B 68
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN MONOCYTES FROM PATIENTS WITH SYSTEMIC SCLEROSIS AND CORRELATION WITH THEIR SEROLOGICAL PROFILE 67
Ruolo degli autoanticorpi nelle patologie autoimmuni 66
Metodo ELISA: dosaggio della catena pesante della molecola HLA non associata alla b2-microglobulina 64
Phlegmonous abscess associated with etanercept therapy 63
Peptidi che mimano l'antigene CD20: potenzialità terapeutiche nel lupus eritematoso sistemico 62
Functional characterization of peptides mimicking the CD20 epitope recognized by Rituximab 60
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides. Journal of Immunology 60
Poems syndrome with amyloidosis and calchyphylaxis.A case report 59
Two structurally different peptides mimic a CD20 epitope recognized by rituximab 59
Endothelial cells in tumor microenvironment: insights and perspectives 57
Quantitative evaluation of anti-FOXE-3 Ab identifies a subset of anti-CENP positive systemic sclerosis patients who are less prone to develop active disease 56
Generation of linear and cyclic peptides revealed a unique fine specificity of Rituximab and its possible cross-reactivity with an acid sphingomyelinase-like phosphodiesterasem 3B precursor 54
 Peptides highly specific to the variable region of TNF-ALFA-specific references licensed (RL) monoclonal antibodies (MAB), as potential tool to effectively assess similarity between biosimilars and the correspondig RL MAB 52
Chronic-Relapsing cutaneous leukocytoclastic vasculitis in a young patient with reduced EBV-specific T cell response using enzyme-linked immunospot (ELISPOT) assay successfully treated with Valaciclovir 51
Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces 50
null 49
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 48
Ruolo degli autoanticorpi nelle patologie autoimmuni 46
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity 46
Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study 42
Mimotope peptides in the immunization against CD20: a promising approach to the therapy of autoimmune diseases 40
Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity 37
Classic pyoderma gangrenosum 34
null 33
Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors 30
Methods for treating a tumor using an antibody that specifically binds grp94 30
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 26
Functional characterization of peptides mimicking the CD-20 epitope recognized by Rituximab 24
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 23
β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 19
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma 15
Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 8
Totale 7.170
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.104
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021471 0 0 0 0 0 50 131 83 62 75 36 34
2021/2022522 24 67 6 18 22 34 51 22 32 23 97 126
2022/2023844 122 94 45 74 107 105 29 116 113 9 16 14
2023/2024363 24 53 19 70 21 77 11 21 8 8 6 45
2024/20251.280 79 18 114 20 28 86 158 106 53 67 178 373
2025/20261.480 396 159 181 374 307 63 0 0 0 0 0 0
Totale 7.170